介孔硅纳米颗粒负载氟尿嘧啶用于肝癌和乳腺癌治疗的研究

doi:10.3969/j.issn.1009-976X.2021.03.009

摘要/Abstract

摘要： 目的为了提高抗肿瘤药物的治疗效果,有效降低毒副作用。方法利用溶胶-凝胶法合成介孔硅纳米颗粒（MSN）,负载抗癌药物氟尿嘧啶（5-FU）,得到MSN@5-FU载药纳米材料。首先对MSN@5FU的物理特性进行表征,接下来考察MSN@5FU的载药量,生物相容性以及药物释放情况,最后研究体外杀死肿瘤细胞的效果。结果电镜图可以清晰地观察到,合成的MSN是纳米级尺寸,大小均一,孔径分布明显。同时,合成的MSN具有很强的负载5-FU的能力。此外,该载药系统在溶液中可以长期稳定存在,对正常细胞无毒副作用。重要的是,在微酸环境下可以大量释放5-FU。活死细胞实验结果说明该纳米载药系统具有良好的杀死肿瘤细胞能力。结论 MSN@5FU纳米载药系统在肝癌和乳腺癌治疗中可以发挥重要作用。

关键词: 介孔硅纳米颗粒, 载药量, 细胞活性

Abstract: Objective To improve the therapeutic effect of anti-tumor drugs and effectively reduce the toxic side effects. Methods We synthesized mesoporous silica nanoparticles （MSN） loaded with the anti-tumor drug fluorouracil （5-FU） using the sol-gel method to obtain MSN@5-FU drug-loaded nanomaterials. The physical properties of MSN@5FU were characterized, next the drug loading, biocompatibility and drug release of MSN@5-FU were investigated, and finally the in vitro cancer cell killing effect was studied. Results The electron micrographs clearly observed that the synthesized MSN was nanoscale in size, with uniform size and obvious pore size distribution. Meanwhile, the synthesized MSN has a strong ability to load 5-FU. In addition, the drug loading system can exist stably in solution for a long time without toxic side effects on normal cells. Importantly, a large amount of 5-FU can be released in a micro-acidic environment. the results of live-dead cell experiments indicate that the nano-loaded system has good ability to kill cancer cells. Conclusion The MSN@5-FU nanodrug delivery system can play an important role in the treatment of hepatic and breast cancer.

Key words: mesoporous silica nanoparticles, loading capacity, cell viability

中图分类号:

R737.9

宋洋, 钟克力. 介孔硅纳米颗粒负载氟尿嘧啶用于肝癌和乳腺癌治疗的研究[J]. 岭南现代临床外科, 2021, 21(03): 298-301.

SONG Yang, ZHONG Ke-li. Mesoporous silica nanoparticle-loading 5-Fluorouracil for potent antitumor effect against hepatic cancer and breast cancer cells[J]. Lingnan Modern Clinics In Surgery, 2021, 21(03): 298-301.

参考文献

[1] Dai Y, Xu C, Sun X, et al.Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment[J]. Chem Soc Rev, 2017, 46(12): 3830-3852.
[2] Liu Z, Chen X.Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy[J]. Chem Soc Rev, 2016, 45(5): 1432-1456.
[3] Zhou Z, Song J, Nie L, Chen X.Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy[J]. Chem Soc Rev, 2016, 45(23): 6597-6626.
[4] Zhou L, Jiang Y, Yan T, et al.The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures[J]. Breast Cancer Res Treat, 2010, 122(3): 795-801.
[5] Ferrari M.Cancer nanotechnology: opportunities and challenges[J]. Nat Rev Cancer, 2005, 5(3): 161-171.
[6] Shi J, Kantoff PW, Wooster R, Farokhzad OC.Cancer nanomedicine: progress, challenges and opportunities[J]. Nat Rev Cancer, 2017, 17(1): 20-37.
[7] Davis ME, Chen Z, Shin DM.Nanoparticle therapeutics: an emerging treatment modality for cancer[J]. Nat Rev Drug Dis, 2008, 7(9): 771-782.
[8] Agasti SS, Rana S, Park MH, et al.Nanoparticles for detection and diagnosis[J]. Adv Drug Deliv Rev, 2010, 62(3): 316-328.
[9] Salonen J, Kaukonen AM, Hirvonen J, Lehto VP.Mesoporous Silicon in Drug Delivery Applications[J]. J Pharm Sci, 2008, 97(2): 632-653.
[10] Qian KK, Bogner RH.Application of Mesoporous Silicon Dioxide and Silicate in Oral Amorphous Drug Delivery Systems[J]. J Pharm Sci, 2012, 101(2): 444-463.
[11] Zhang J, Zhang J, Li W, et al.Degradable Hollow Mesoporous Silicon/Carbon Nanoparticles for Photoacoustic Imaging-Guided Highly Effective Chemo-Thermal Tumor Therapy in Vitro and in Vivo[J]. Theranostics, 2017, 7(12): 3007-3020.
[12] Yu X, Yang K, Chen X, Li W.Black hollow silicon oxide nanoparticles as highly efficient photothermal agents in the second near-infrared window for in vivo cancer therapy[J]. Biomaterials, 2017, 143: 120-129.
[13] Prestidge CA, Barnes TJ, Lau CH, et al.Mesoporous silicon: a platform for the delivery of therapeutics[J]. Expert Opin Drug Deliv, 2007, 4(2): 101-110.
[14] Li S, Zhang Y, He XW, et al.Multifunctional mesoporous silica nanoplatform based on silicon nanoparticles for targeted two-photon-excited fluorescence imaging-guided chemo/photodynamic synergetic therapy in vitro[J]. Talanta, 2020, 209: 120552.
[15] Kline CL, Sheikh HS, Scicchitano A, et al.Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients[J]. Cancer Biol Ther, 2011, 12(7): 557-568.
[16] Beumer JH, Chu E, Allegra C, et al.Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy[J]. Clin Pharmacol Ther, 2019, 105(3): 598-613.
[17] Schaaf LJ, Dobbs BR, Edwards IR, Perrier DG.Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients[J]. Eur J Clin Pharmacol, 1987, 32(4): 411-418.
[18] Yang CG, Ciccolini J, Blesius A, et al.DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity[J]. Cancer Chemother Pharmacol, 2011, 67(1): 49-56.
[19] Xie W, Deng WW, Zan M, et al.Cancer Cell Membrane Camouflaged Nanoparticles to Realize Starvation Therapy Together with Checkpoint Blockades for Enhancing Cancer Therapy[J]. ACS Nano, 2019, 13(3): 2849-2857.